407 related articles for article (PubMed ID: 30692052)
1. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
Wolfe GI; Kaminski HJ; Aban IB; Minisman G; Kuo HC; Marx A; Ströbel P; Mazia C; Oger J; Cea JG; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BRF; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Verschuuren JJGM; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Silvestri NJ; Conwit R; Sonett JR; Jaretzki A; Newsom-Davis J; Cutter GR;
Lancet Neurol; 2019 Mar; 18(3):259-268. PubMed ID: 30692052
[TBL] [Abstract][Full Text] [Related]
2. Minimal manifestation status and prednisone withdrawal in the MGTX trial.
Lee I; Kuo HC; Aban IB; Cutter GR; McPherson T; Kaminski HJ; Sussman J; Ströbel P; Oger J; Cea G; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BRF; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Verschuuren JJG; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Conwit R; Minisman G; Sonett JR; Wolfe GI;
Neurology; 2020 Aug; 95(6):e755-e766. PubMed ID: 32611638
[TBL] [Abstract][Full Text] [Related]
3. Randomized Trial of Thymectomy in Myasthenia Gravis.
Wolfe GI; Kaminski HJ; Aban IB; Minisman G; Kuo HC; Marx A; Ströbel P; Mazia C; Oger J; Cea JG; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BR; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Garcia Ramos GS; Verschuuren JJ; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Conwit R; Odenkirchen J; Sonett JR; Jaretzki A; Newsom-Davis J; Cutter GR;
N Engl J Med; 2016 Aug; 375(6):511-22. PubMed ID: 27509100
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of thymectomy plus prednisone compares with prednisone monotherapy for the treatment of non-thymomatous Myasthenia Gravis: Protocol for a systematic review.
Yang H; Liu D; Hong X; Sun H; Zheng Y; Yang B; Wang W
Medicine (Baltimore); 2020 Jun; 99(25):e20832. PubMed ID: 32569233
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.
McPherson T; Aban I; Duda PW; Farzaneh-Far R; Wolfe GI; Kaminski HJ; Cutter G; Lee I;
Muscle Nerve; 2020 Aug; 62(2):261-266. PubMed ID: 32369631
[TBL] [Abstract][Full Text] [Related]
6. [The Significance of Extended Thymectomy in Non-Thymomatous Myasthenia Gravis: an MGTX Study].
Yoshikawa H
Brain Nerve; 2017 Jan; 69(1):51-59. PubMed ID: 28126978
[TBL] [Abstract][Full Text] [Related]
7. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone.
Newsom-Davis J; Cutter G; Wolfe GI; Kaminski HJ; Jaretzki A; Minisman G; Aban I; Conwit R
Ann N Y Acad Sci; 2008; 1132():344-7. PubMed ID: 18567886
[TBL] [Abstract][Full Text] [Related]
8. [Current status and future prospects of therapy for myasthenia gravis: considering thymectomy].
Yoshikawa H; Iwasa K; Takamori M
Brain Nerve; 2011 Jul; 63(7):729-36. PubMed ID: 21747143
[TBL] [Abstract][Full Text] [Related]
9. Optimal timing of thymectomy in nonthymomatous myasthenia gravis patients in China: A prospective study.
Pan J; Jiang Q; Liu F; Wen Y
Medicine (Baltimore); 2018 Sep; 97(38):e12499. PubMed ID: 30235757
[TBL] [Abstract][Full Text] [Related]
10. [International project--MGTX study].
Yoshikawa H
Rinsho Shinkeigaku; 2007 Nov; 47(11):880-2. PubMed ID: 18210825
[TBL] [Abstract][Full Text] [Related]
11. [Thymectomy in thymomatous and non-thymomatous myasthenia gravis: analysis of a cohort of 46 patients].
Cabrera-Maqueda JM; Alba-Isasi MT; Hernández R; Arroyo-Tristán A; Morales-Ortiz A
Rev Neurol; 2020 Mar; 70(6):213-219. PubMed ID: 32149381
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
[TBL] [Abstract][Full Text] [Related]
13. Is thymectomy in non-thymomatous myasthenia gravis of any benefit?
Diaz A; Black E; Dunning J
Interact Cardiovasc Thorac Surg; 2014 Mar; 18(3):381-9. PubMed ID: 24351507
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
15. Analysis of outcomes following surgical treatment of thymolipomatous myasthenia gravis: comparison with thymomatous and non-thymomatous myasthenia gravis.
Huang CS; Li WY; Lee PC; Kao KP; Chou TY; Wu MH; Hsu HS; Wu YC; Hsu WH; Huang BS
Interact Cardiovasc Thorac Surg; 2014 Apr; 18(4):475-81. PubMed ID: 24366316
[TBL] [Abstract][Full Text] [Related]
16. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study.
Ponseti JM; Gamez J; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Armengol M
Curr Med Res Opin; 2007 Jun; 23(6):1269-78. PubMed ID: 17559724
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V; Drużdż A; Grosskreutz J; Habib AA; Mantegazza R; Sacconi S; Utsugisawa K; Vissing J; Vu T; Boehnlein M; Bozorg A; Gayfieva M; Greve B; Woltering F; Kaminski HJ;
Lancet Neurol; 2023 May; 22(5):383-394. PubMed ID: 37059507
[TBL] [Abstract][Full Text] [Related]
18. Myasthenia gravis with thymoma: analysis of and postoperative prognosis for 65 patients with thymomatous myasthenia gravis.
Monden Y; Nakahara K; Kagotani K; Fujii Y; Masaoka A; Kawashima Y
Ann Thorac Surg; 1984 Jul; 38(1):46-52. PubMed ID: 6732348
[TBL] [Abstract][Full Text] [Related]
19. [The value of thymectomy in the treatment of non-thymomatous myasthenia gravis].
Menghesha H; Schroeter M; Doerr F; Schlachtenberger G; Heldwein MB; Chiapponi C; Wahlers T; Bruns C; Hekmat K
Chirurg; 2022 Jan; 93(1):48-55. PubMed ID: 34132824
[TBL] [Abstract][Full Text] [Related]
20. Long-term prednisone followed by thymectomy in myasthenia gravis.
Mann JD; Johns TR; Campa JF; Muller WH
Ann N Y Acad Sci; 1976; 274():608-22. PubMed ID: 1066998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
